Загрузка...
Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia
Gemtuzumab ozogamicin (GO), a humanized anti-CD33 monoclonal antibody conjugated to the cytotoxic antibiotic agent calicheamicin, is approved for the treatment of newly-diagnosed CD33 + AML in adults and children ≥ 1 month old, and relapsed or refractory CD33 + AML in adults and children ≥ 2 years o...
Сохранить в:
| Опубликовано в: : | J Hematol Oncol |
|---|---|
| Главные авторы: | , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
BioMed Central
2020
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7559451/ https://ncbi.nlm.nih.gov/pubmed/33059764 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-020-00975-2 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|